ct-p63
mAbexperimentalCOVID-19
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Sep 24, 2021 (NCT05017168)
Timeline
Indications
Studied for
Mechanism of action
- Spike glycoproteinANTAGONIST
Spike glycoprotein antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05224856 | Phase 3 | Apr 30, 2022 | Celltrion |
| NCT05017168 | Phase 1 | Sep 24, 2021 | Biokinetica S.A., Celltrion |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celltrion | For profit | 2 | 2 | 2 | 2021 |
| Biokinetica S.A. | For profit | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1